...
首页> 外文期刊>Anais da Academia Brasileira de Ciencias >Physicochemical quality profiles of commercial oral tablets and capsules containing lutein – impact of insufficient specific sanitary regulations
【24h】

Physicochemical quality profiles of commercial oral tablets and capsules containing lutein – impact of insufficient specific sanitary regulations

机译:含有叶黄素的商业口服片剂和胶囊的理化质量特征–特定卫生法规不足的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Dietary supplements in many countries such as the USA do not require registration prior to commercialization. The Agência Nacional de Vigilancia Sanitária (ANVISA) registers substances with functional properties as foods. Lutein is a carotenoid with antioxidant activity available on the market. However, no regulatory mandates exist to govern the design of quality control tests, which are necessary to ensure formulation effectiveness. Therefore, in the present study, tablet and dosage formulations from different manufacturers were tested following general methods outlined in the Brazilian and American Pharmacopeias. The averageweight, disintegration, content and dose uniformity assays were performed for all tablets and capsules, whereas hardness assays were only performed on tablets. None of the 10 formulations studied were found to be of satisfactory quality. Of all tablets tested, two had no-significant available lutein content, which may indicate adulteration. The capsules displayed adequate amounts of lutein, however had alarmingly negative disintegration and dissolution test results, which may contribute to non-bioavailability of lutein. All formulations analyzed are currently being marketed in the Brazilian and American markets. The low physicochemical performance in these formulations can be explained by the lack of specific regulations, which are necessary to ensure the quality of lutein-containing products on the market.
机译:许多国家(例如美国)的膳食补充剂在商业化之前不需要注册。阿根廷圣维吉尼亚州农牧业总署(ANVISA)将具有功能特性的物质注册为食品。叶黄素是市场上有售的具有抗氧化活性的类胡萝卜素。但是,不存在管理质量控制测试设计的法规要求,这对于确保配方的有效性是必不可少的。因此,在本研究中,按照巴西和美国药典中概述的一般方法测试了来自不同制造商的片剂和剂型。对所有片剂和胶囊剂进行平均重量,崩解,含量和剂量均匀性测定,而硬度测定仅在片剂上进行。发现所研究的10种制剂均没有令人满意的质量。在所有测试的片剂中,有两片的叶黄素含量不显着,这可能表明掺假。胶囊显示出足够量的叶黄素,但是令人震惊的负崩解和溶出度测试结果可能导致叶黄素的非生物利用度。目前,所有分析的配方都在巴西和美国市场上销售。这些制剂中低的理化性能可以通过缺乏特定法规来解释,这些法规对于确保市场上含有叶黄素的产品的质量是必需的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号